Back

CG-806 for Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin’s Lymphomas

  • Clinical Trial Information

    Trial Contact: Donaldson, Karin M; Frankos, Marie

    Trial Phone: 321.841.9821 ; 321.841.7303

  • IRB No: WIRB 20190544

    Protocol Abbrev: TRIO APTO-CG-806-01

    Principal Investigator: Jose E. Sarriera, MD

    Phase: Drug: Phase I

    Age Group: Adult

    Secondary Protocol No: APTO-CG-806-01

    Treatment: CG-806 will be given in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached

    Therapies Involved: Chemotherapy;Oncology: 3rd line/Refractory

    ClinicalTrials.gov ID: NCT03893682

  • Objective

    This study is being done to evaluate the safety, tolerability and effectiveness of CG-806 for the treatment of patients with the condition of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for general well being.

  • Key Eligibility

    Pathologically documented relapsed or refractory B cell NHL or CLL/SLL who have failed or are intolerant to 2 or more lines of established therapy, or for whom no other treatment options are available in the opinion of the investigator